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changes in treatments’ effect on weight and HbA1c, and in utility values related to 
weight changes. Dapagliflozin’s higher health benefits and cost savings are mainly 
explained by its greater beneficial effect on weight, leading to higher QALYs and less 
drug costs for dapagliflozin patients. The lower treatment costs are related to the 
insulin treatment costs (i.e. subsequent line regimens) due to the lower weight of 
dapagliflozin patients observed over time, which eventually leads to lesser insulin 
dosage. ConClusions: Dapagliflozin is a cost-saving strategy with higher health 
benefits compared to DPP4, added to metformin, for Turkish T2DM patients inad-
equately controlled on metformin mono-therapy.
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objeCtives: Economic modelling in type 1 diabetes mellitus (T1DM) is complex and 
continuously evolving. The aim of this systematic review was to assess methodologi-
cal capabilities of T1DM models. Methods: A systematic search was undertaken 
in MEDLINE®, Embase®, and the Cochrane library to identify economic evaluation 
models in T1DM (English language until November 2014). The websites of HTA bod-
ies in England, Canada, Australia, France, Germany, Scotland and Spain were also 
screened. Study inclusion was based on a pre-specified protocol and carried out by a 
team of reviewers and information scientists independently, and data was extracted 
focusing on methodological capabilities. Results: 74 publications describing 13 
unique models were identified. Most models employed a Markov structure, and 
all included microvascular complications while five included both microvascu-
lar and macrovascular complications. Patient-level (microsimulation) and cohort 
approaches were equally common. While naturally varying across models, the risk 
equations that simulated event rates were generally based on a small set of studies 
which are now more than 20 years old. Treatment-effects were simulated in several 
ways; the more comprehensive models used surrogate risk factors (mostly HbA1c) to 
modify the risk of complications, but other approaches included directly modifying 
complication rates, quality-of-life, and/or resource use. The most common adverse 
events included in the models were hypoglycemia and ketoacidosis. Although the 
details provided varied, five models explicitly reported probabilistic sensitivity 
analysis capabilities. ConClusions: There was considerable heterogeneity in 
the models, likely driven by varying intended uses. The sub-set of models clearly 
intended for cost-effectiveness applications used more sophisticated approaches to 
capturing uncertainty and were among the most comprehensive, tending to include 
both micro- and macrovascular outcomes and common treatment-related adverse 
events. These models are likely to provide the most useful set of model capabilities 
despite relying on aging risk equations.
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objeCtives: To estimate the cost-effectiveness of using CANA versus DAPA or EMPA, 
three agents that inhibit sodium glucose co-transporter 2 (SGLT2), as monotherapy 
from the UK NHS perspective. Methods: The validated ECHO-T2DM model was 
used to estimate 40-year outcomes and costs associated with using CANA 100 or 
300mg versus DAPA 10mg or EMPA 25mg. Data from a 26-week network meta-analysis 
(NMA) performed to support a NICE multiple technology assessment were used to 
populate the model with treatment effects for HbA1c, blood pressure, weight and rates 
of hypoglycaemic events (hypoglycaemia data for EMPA were not possible to report 
from the NMA). Changes in lipids and rates of adverse events (AEs) associated with 
SGLT2 inhibition (i.e., urinary tract infections, genital mycotic infections) were sourced 
from a CANA monotherapy trial; values for DAPA and EMPA were assumed the same 
as CANA 100mg (as was the hypoglycaemia rate for EMPA). Sensitivity analyses were 
also performed. Results: In the base case, CANA 100mg dominated DAPA and EMPA 
with quality-adjusted life-year (QALY) gains of 0.033 and 0.015 and lower total costs of 
£69 and £3. CANA 300mg versus DAPA provided an estimated QALY gain of 0.075 and 
increased cost of £709, resulting in an incremental cost-effectiveness ratio (ICER) of 
£9,429. Versus EMPA, the ICER was slightly higher (£13,491), but still below the gener-
ally accepted threshold in the UK, with a QALY gain of 0.056 and an increased cost 
of £761. Sensitivity analyses supported these base case findings. ConClusions: 
Through an insulin-independent mechanism of action, agents that inhibit SGLT2 
improve glucose levels, blood pressure, and weight, with a low inherent risk of hypo-
glycaemia. These results suggest that both CANA 100 and 300mg are likely to be 
cost-effective monotherapy options versus DAPA and EMPA in the UK.
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objeCtives: Gestational diabetes mellitus (GDM) is associated with elevated risk 
of severe perinatal complications and type 2 diabetes (T2DM). Screening and inter-
vention is recognized as an effective way to reduce these risks. The prevalence rate 
of GDM was as high as 17.5% in China, which caused a huge economic burden. 
GDM screening and intervention was reported in many hospitals in China, however, 
lacking evaluation from an economic perspective up to now. The objective was 
to estimate the long-term cost-effectiveness associated with GDM screening in 
the urban Chinese setting to provide economic evidence for clinical practice and 
1National School of Public Health, Athens, Greece, 2Athens University Medical School, Athens, 
Greece, 3Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), Athens, 
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objeCtives: To evaluate the long-term cost-effectiveness of dapagliflozin versus 
a sulfonylurea (SU) or a dipeptidyl-peptidase-IV (DPP-4) inhibitor, when added to 
metformin, in Type 2 diabetes mellitus (T2DM) patients inadequately controlled on 
metformin in Greece. Methods: The published and validated CARDIFF diabetes 
model, a lifetime micro-simulation model, was adapted to the Greek health care 
setting to determine the incidence of micro- and macro-vascular complications 
and diabetes-specific and all-cause mortality. Clinical inputs were derived from a 
52-week randomized clinical trial and a network meta-analysis comparing dapa-
gliflozin with SU and DPP-4 inhibitor, respectively, in combination with metformin. 
Local unit costs and utility data were retrieved from literature and assigned to model 
parameters to calculate total quality-adjusted life years (QALYs) and total costs as 
well as incremental cost-effectiveness ratios (ICERs).The analysis was conducted 
from the perspective of a third-party payer in Greece. Uncertainty surrounding 
important model parameters was explored with probabilistic sensitivity analysis 
(PSA). Results: Over a patient’s lifetime, dapagliflozin was associated with 0.488 
(95% CI: 0.477-0.5) and 0.042 (95% CI: 0.03-0.054) incremental QALYs compared 
with SU and DPP-4 inhibitor, respectively, at additional costs of € 5,149 (95% CI: 
€ 5,026-€ 5,272) and € 755 (95% CI: € 636-€ 874), respectively. These findings were mainly 
driven by the beneficial effect of dapagliflozin on weight, and its higher drug acqui-
sition costs. The corresponding ICERs were € 10,545 and € 17,871 per QALY gained 
versus the treatment with SU and DPP-4, respectively. At the defined willingness-
to-pay threshold of € 34,000 per QALY gained, PSA results showed that treatment 
with dapagliflozin was estimated to have a 99% and 57.5% probability of being cost-
effective relative to the SU and DPP-4 treatments. ConClusions: Dapagliflozin in 
combination with metformin was shown to be a cost-effective treatment alterna-
tive for patients with T2DM whose metformin regimen does not provide sufficient 
glycemic control in the current Greek health care setting.
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objeCtives: Dulaglutide 1.5mg once weekly is a novel glucagon-like peptide 1 
receptor (GLP-1) agonist, for the treatment of type 2 diabetes mellitus (T2DM). 
The objective of this analysis was to estimate the cost-effectiveness of dulaglu-
tide versus liraglutide 1.8mg and liraglutide 1.2mg for the treatment of T2DM in 
Sweden. Methods: The IMS CORE Diabetes Model (CDM), a validated simula-
tion model, was used to estimate expected costs and outcomes. The compara-
tors investigated were liraglutide 1.8mg and liraglutide 1.2mg. In accordance 
with Swedish guidelines the analysis was conducted using a societal perspective 
including Swedish-specific direct and indirect costs over a lifetime time horizon. 
Comparative safety and efficacy data were derived from direct comparison of 
dulaglutide 1.5mg versus liraglutide 1.8mg from the AWARD-6 trial and from a 
network meta-analysis for the comparison of dulaglutide 1.5mg versus liraglutide 
1.2mg. One-way and probabilistic sensitivity analyses were conducted to explore 
the sensitivity of the model to plausible variations in key parameters and over-
all uncertainty. Results: Under base case assumptions, dulaglutide 1.5mg was 
found to be less costly and more effective versus liraglutide 1.8mg (total costs 
1,032,258 SEK vs 1,045,927 SEK; total QALYS 8.062 vs 8.033 for dulaglutide 1.5mg 
and liraglutide 1.8mg, respectively) and liraglutide 1.2mg (total costs 1,048,832 SEK 
vs 1,051,224 SEK; total QALYs 8.016 vs 7.974 for dulaglutide 1.5mg and liraglutide 
1.2mg, respectively). One-way sensitivity analyses demonstrated that dulaglutide 
1.5mg remained dominant versus liraglutide 1.8mg given plausible variations in 
key input parameters. Results of the probabilistic sensitivity analysis were con-
sistent with base case results. ConClusions: In the base case, the model found 
that dulaglutide 1.5mg was more effective and less costly than liraglutide 1.8mg 
and liraglutide 1.2mg for the treatment of T2DM in Swedish setting. Findings were 
robust to plausible variations in inputs. The introduction of dulaglutide 1.5mg may 
result in societal cost savings.
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objeCtives: Dapagliflozin, a sodium-glucose-transporter-protein-2 (SGLT2) inhibi-
tor, can serve as a treatment for type 2 diabetes mellitus (T2DM) in patients inad-
equately controlled on metformin mono-therapy. The relative health benefits and 
costs of dapagliflozin compared to a dipeptidyl-peptidase-4 inhibitor (DPP4), added 
to metformin, were assessed through a cost-effectiveness analysis (CEA) from a 
Turkish payer perspective. Methods: For the current CEA, a micro-simulation 
disease model (CARDIFF) was used. Clinical inputs were derived from a system-
atic review and network meta-analysis, along with a long-term follow-up study 
for dapagliflozin. In addition, Turkish specific cost data were collected and applied. 
The model predicted micro-and macro-vascular complications based on the UKPDS 
equations. Total Quality-Adjusted-Life-Years (QALYs) and costs were calculated over 
a lifetime horizon. Deterministic, probabilistic sensitivity analyses and elaborate 
scenario analyses were performed. Results: Compared to DPP4, dapagliflozin 
was associated with an incremental benefit of 0.590 QALYs (95% CI: 0.038; 1.232) 
and cost savings of TRY 494 (95% CI: TRY-1,727; TRY 889). Results were sensitive to 
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objeCtives: Despite relevant treatments, only 29% of type 2 diabetes (T2DM) 
patients in Greece achieve their pre-defined glycemic targets. When treatment 
with metformin (MF) fails to control T2DM patients, add-on therapies are needed. 
Sitagliptin is indicated as second-line therapy in Greece, after treatment with MF 
has failed and is a valid option in the proposed national therapeutic protocols. 
The present study aimed to assess the cost-effectiveness of adding Sitagliptin to 
MF vs adding sulphonylurea (SU) to MF for the treatment of T2DM patients with 
inadequate glycemic control. Methods: A published individual-level simulation 
model was developed to simulate the lifetime medical cost, diabetic complications, 
drug-related adverse events, life expectancy and quality adjusted life years (QALYs) 
associated with Sitagliptin add-on therapy versus SU add-on therapy. The model is 
developed based upon the UKPDS 68 risk equations to project long-term complica-
tions and mortalities. Efficacy and safety profiles of drugs were obtained from a 
head-to-head trial. Costs (€ 2014 prices) and effects were discounted at 3.5% annu-
ally. Greek data retrieved by an expert input forum of specialists. Sensitivity analyses 
performed on 17 parameters. Analysis based on Greek payer perspective. Results: 
Sitagliptin strategy is projected to cost 359 EUR more than SU strategy per patient 
over lifetime. Sitagliptin showed reductions in diabetes-related complications and 
adverse events. The incremental QALY for Sitagliptin strategy is 0.042, primarily 
driven by the improved outcomes associated with hypoglycemia, body weight 
change, and MI. The incremental cost effectiveness ratio (ICER) is 8,582 € /QALY 
gained. Sensitivity analysis conducted varied multiple parameters. ICER ranges 
from 4,873 to 12,173 € /QALY gained. The results are robust and never exceeded the 
30,000€ /QALY threshold. ConClusions: Sitagliptin add-on strategy could be cost-
effective, compared to SU, for the Greek healthcare setting. Furthermore, it remains 
cost-effective in all types of sensitivity analysis.
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objeCtives: to assess the cost effectiveness of saxagliptin (SAXA) vs sitagliptin 
(SITA) or vildagliptin (VILDA) as add-on therapy to metformin (MET) in patients with 
type 2 diabetes mellitus (T2DM) and inadequate glycaemic control on metformin 
alone. Methods: the Cardiff Diabetes Model was adapted to the Russian health-
care setting. We modeling events, efficacy, total costs for managing patients with 
T2DM: 1-st line – monotherapy metformin alone, 2-nd line (target groups) – SAXA or 
SITA or VILDA plus metformin, 3-nd line – insulin rescue therapy. The model simu-
lated the disease progression and treatment effects for 40 years (8-26-6 years for 
1-2-3 lines respectively). The effectiveness measure was quality-adjusted life years 
(QALYs) gained per patient. Results: in case short-time efficacy (decrease HBA1c 
-1%) cost-effectiveness ratio (CER) for SAXA+MET was the lowest: $835 per QALY. 
When compared with SITA+MET for the long-term efficacy (40 years), SAXA+MET 
was the dominant strategy, i.e. less costly (-$505) and more effective (+0.16 QALY). 
When compared to VILDA+MET, SAXA+MET was more costly (+$364), but more 
effective (+0.14 QALY). The incremental cost-effectiveness ratio (ICER) per responder 
for SAXA+MET vs VILDA+MET was estimated at $2,566 per QALY gained and would 
be cost effective at the willingness-to-pay (WTP) threshold $36,373/QALY for 
Russia in 2014. If we used combined medicines: Kombiglyce (SAXA+MET), Janumet 
(SITA+MET) and Galvus Met (VILDA+MET), then Kombiglyce interventions were also 
more efficacious than Janumet and Galvus Met, but were associated with increased 
total costs. The ICERs per responder for Kombiglyce were estimated at $3,216/QALY 
(vs Janumet), $3,269/QALY (vs Galvus Met) and would be cost effective at the WTP 
threshold $36,373/QALY for Russia in 2014. ConClusions: at a willingness-to-pay 
threshold of $36,373/QALY SAXA+MET and Kombiglyce is likely to be a cost-effective 
option for the treatment of T2DM in adult patients in Russia.
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objeCtives: Establish incremental cost-effectiveness ratio (ICER) in cost per 
additional patient with glycemic control for all the oral antidiabetic medications 
available in Colombia, as a second-line treatment for adult patients with type 2 
diabetes (DM2), who do not reach therapeutic targets with metformin and are 
not yet considered candidates for insulin therapy. Methods: Oral antidiabetic 
medications were divided into drug classes: sulfonylureas (divided between glib-
enclamide, other sulphonylureas), thiazolidinediones, GLP-1 receptor agonists, and 
DPP4 inhibitors. A systematic review of the literature was done to obtain transition 
probabilities in a Markov model (monthly cycles, time horizon one year) designed 
to represent the Colombian health system perspective. The main outcome consid-
ered was glycemic control, but data on adherence and adverse events were also 
collected. Costs (in 2014 Colombian pesos; 1 euro = COP 2,660) were estimated 
from base cases obtained from multidisciplinary expert panel meetings, with 
local costs applied from national tariff manuals and official drug price registries. 
Sensitivity analyses were performed. Results: Annual treatment costs ranged 
from € 116 for glibenclamide, and € 98 for other sulphonylureas, to € 12,205 for 
GLP-1 receptor agonists. Number of patients with glycemic control (per 1000) were 
glibenclamide 145, sulphonylureas 265, thiazolidinediones 472, GLP-1 receptor 
agonists 326, and DPP4 inhibitors 417: Compared against other sulfonylureas, 
glibenclamide was dominated, while ICERs per additional patient with glycemic 
control per year would be € 516 for DPP-4 inhibitors, € 712 for thiazolidinediones 
and € 66,790 for GLP-1 receptor agonists. Critical variables in the sensitivity analy-
ses were drug costs (particularly for GLP-1 receptor agonists), but also patient 
policy making. Methods: A published decision-analysis tool (the GeDiForCETM) 
was employed to assess cost-effectiveness of GDM screening by comparing costs 
and averted disability-adjusted life years (DALYs) with no GDM screening. As mod-
eling inputs, costs for GDM screening and antenatal care, incidence and cost of 
GDM perinatal adverse effects (PAE) were based on an investigation on 6 tertiary 
hospitals from different cities in China as part of this analysis. Cost for postpartum 
care was calculated based on literature and adjusted for China. PAE-DALYs, life-
time cost for postpartum T2DM, and effectiveness of interventions were collected 
from literature. Annual discount rate was 3.0%. One-way sensitivity analyses were 
conducted on some key indicators. Results: The total costs of GDM screening, 
intervention and life-time treatment per 1000 pregnant women were $7,092,398 in 
GDM screening group, saving $1,329,671 comparing with no screening. 277.4 DALYs 
were averted in screening group, which was mainly brought out by GDM postpartum 
care for T2DM prevention. Sensitivity analyses demonstrated robustness of the 
results. ConClusions: GDM screening and interventions are cost-saving in an 
urban Chinese setting by IADPSG standards. As DALYs averted mainly comes from 
T2DM prevention, China should pay more attention to providing postpartum care 
for GDM women in the future.
PDB61
coSt of ReAching DefineD hBA1c tARget uSing cAnAgliflozin 
comPAReD to DAPAgliflozin AS ADD-on to metfoRmin in PAtientS with 
tyPe 2 DiABeteS mellituS (t2Dm) in the uniteD ARAB emiRAteS (uAe)
Schubert A1, Nielsen AT2, El Khoury A3, Kamal A3, Taieb V4
1Janssen-Cilag Poland, Warsaw, Poland, 2Janssen-Cilag A/S, Birkerød, Denmark, 3Janssen-Cilag, 
Dubai, United Arab Emirates, 4Amaris, London, UK
objeCtives: Improving glycaemic control is the primary goal of T2DM manage-
ment and can help to reduce the risk of micro- and macrovascular complications. 
Guidelines from the American Diabetes Association and European Association for 
the Study of Diabetes recommend lowering HbA1c to levels < 7.0% for most patients. 
This analysis compared the cost of reaching this target (HbA1c < 7.0%) using cana-
gliflozin versus dapagliflozin, two compounds that inhibit sodium glucose co-trans-
porter 2 (SGLT2), in dual therapy as add-on to metformin from the payer perspective 
in the UAE. Methods: A Bayesian network meta-analysis (NMA) was conducted 
to compare the efficacy of canagliflozin 100 and 300 mg versus dapagliflozin 10 
mg in terms of the percentage of patients that achieved the HbA1c goal of < 7.0% 
at 26 weeks. Based on the NMA results and the acquisition cost of dapagliflozin 
in the UAE ($1.77 per day), we calculated what the daily acquisition cost of each 
dose of canagliflozin would be if the costs of a patient reaching the target with 
canagliflozin 100 and 300 mg were equalized to the cost of reaching the target with 
dapagliflozin 10 mg. Results: In dual therapy as add-on to metformin, patients 
using canagliflozin 100 and 300 mg were more likely to achieve HbA1c < 7.0% com-
pared to those using dapagliflozin 10 mg, with odds ratios of 1.3 (Pr= 82%) and 1.7 
(Pr= 96%), respectively. The costs of canagliflozin 100 and 300 mg that equalized the 
cost of reaching HbA1c < 7.0% with dapagliflozin 10 mg were $2.11 and $2.45 per 
day, respectively. ConClusions: These results suggest that adding canagliflozin 
100 or 300 mg instead of dapagliflozin 10 mg in patients inadequately controlled 
on metformin would result in a more efficient use of resources with costs per day 
up to these break-even levels.
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objeCtives: This study was designed to assess the cost-effectiveness of vildagliptin 
versus glimepiride as add-on to metformin in the management of type 2 diabetes 
mellitus (T2DM) patients in the Greek healthcare setting. Methods: A cost-effec-
tiveness model was designed, using MS Excel, to compare two treatment strategies. 
Strategy 1 consisted of first-line metformin, followed by metformin + vildagliptin in 
second-line, and metformin + basal insulin and metformin + basal + rapid insulin 
in subsequent lines. Strategy 2 differed from strategy 1 only in second-line, where 
metformin was administered with glimepiride. Clinical data and utilities were taken 
from the published literature. Only direct medical costs were included in the analy-
sis (cost base year 2014), and consisted of drug, side-effect and comorbidity costs 
(taken from local officially published sources and the literature). The perspective 
adopted was that of the Social Insurance Fund. The time horizon was lifetime, and 
costs and outcomes were discounted at 3.5%. Results: Adding vildagliptin to met-
formin increased drug costs compared with adding glimepiride to metformin (€ 2,853 
vs. € 2,427, respectively). However, this increase was completely offset by a decrease 
in the costs of associated comorbidities (€ 4,393 vs. € 4,539) and side-effects (€ 3,015 vs. 
€ 3,510), resulting in a lower total cost of € 214.6 in strategy 1 compared with strategy 
2. Comorbidities were the largest cost component in both strategies, accounting for 
42.8% and 43.3% in strategies 1 and 2, respectively. Strategy 1 was also associated 
with increased life-years (LYs, 0.11) and quality-adjusted life-years (QALYs, 0.11) 
compared with strategy 2. Strategy 1 is therefore dominant, as it is associated with 
both lower overall costs and increased effectiveness. ConClusions: Vildagliptin as 
add-on treatment to metformin in the management of T2DM in Greece appears to 
be dominant vs. glimepiride in terms of both cost per LY and cost per QALY gained.
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